Previous Events
11th October 2023 6:00PM BST – Virtual
BRUKINSA®▼ (zanubrutinib): A BTK inhibitor with a difference – Shaping the future of CLL treatment in Scotland
This live virtual meeting brought together expert clinicians to discuss BRUKINSA, a next-generation BTK inhibitor, as a treatment option for patients with CLL. Topics included clinical evidence supporting the use of BRUKINSA, patient case studies, the use of BRUKINSA in the NHS, and concluded with a panel-led Q&A session. On-demand video content from this meeting […]
5th September 2023 6:00PM BST – Virtual
A BTK inhibitor with a difference – Shaping the future of CLL treatment
This meeting was a live-streaming event in which expert clinicians discussed BRUKINSA®▼, a next-generation BTK inhibitor, as a treatment option for patients with CLL. The agenda and speaker information can be found below. Topics included: Agenda Recordings BRUKINSA® : A next-generation BTK inhibitor – Dr Talha Munir BSH Guidelines: BRUKINSA® in CLL – Dr Renata […]
5th July 2023 6:00PM BST – Virtual
Real world experience treating WM and what’s next for CLL
This promotional meeting, sponsored by BeiGene, brought together a group of clinical experts to discuss their experience of treating patients with Waldenstrom’s Macroglobulinaemia using BRUKINSA®▼ (zanubrutinib), a next generation BTK inhibitor. This meeting involved sharing case studies and discussing the role of BRUKINSA in treatment pathways and hospital protocols. The second part of the meeting focused on the role […]
30th November 2022 6:30PM GMT – Virtual
The changing landscape of Waldenström’s Macroglobulinemia (WM) in Scotland
‘The changing landscape of Waldenström’s Macroglobulinemia (WM) in Scotland’ was a live virtual meeting. agenda Discussion topic Discussion Lead Welcome Dr Pam McKay The history and background of WM in Scotland Dr Pam McKay Current treatments: BSH guidelines Dr Dima El-Sharkawi An in-depth look at the ASPEN study Dr Shirley D’Sa and Dr Roger OwenDr […]
1st November 2022 3:00PM GMT – Virtual
The changing landscape of Waldenström’s Macroglobulinemia (WM)
The purpose of this meeting was to discuss the use of BRUKINSA®▼ (zanubrutinib), a next generation BTK inhibitor, in clinical practice and start the conversation about its place in the patient’s treatment pathway and in hospital protocols. The aim was to facilitate the exchange of best practice and expert opinion in order to benefit patients […]